Gorman Joint School District

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results

Retrieved on: 
Friday, November 18, 2022

Cost of Revenues: Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021.

Key Points: 
  • Cost of Revenues: Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021.
  • Research and Development Expenses: Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021.
  • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021.
  • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021.

Twist Bioscience to Present at JSNN NanoImpacts 2022

Retrieved on: 
Wednesday, October 5, 2022

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Eviscerating Pathogenic Microbes While Harmless to Human Skin and Epithelial Eye Cells Granted US Patent

Retrieved on: 
Friday, September 30, 2022

Delicate eyes endure the onslaught of a world of microbes that move unabated and virtually weightless throughout all environments.

Key Points: 
  • Delicate eyes endure the onslaught of a world of microbes that move unabated and virtually weightless throughout all environments.
  • Physical contact with the eye from simple touching and rubbing, to placing contacts represent only a fraction of the ways pathogens infest sensitive organs.
  • The dichotomy of a preservative-free eye solution in an environment contaminated with incomprehensible numbers of harmful pathogens is problematic and limiting.
  • In a world where, "first, do no harm" is sacrosanct, the preponderance of eye solutions contain caustic preservatives that damage epithelial cells.

Patent Promises Global FemTech Opportunity

Retrieved on: 
Wednesday, April 13, 2022

GREENSBORO, N.C., April 13, 2022 /PRNewswire/ -- AT Research Partners has been granted US patent #11,298,375, Brady, et.al. for a contraceptive breakthrough targeting spermatozoa, the "weakest link" in reproduction. The patent was pro se filed and granted in 6 months at a fraught family planning moment, when Texas and other states have been further restricting and seeking to criminalize women's reproductive choices. 

Key Points: 
  • Spermicide Uses Nanoparticles and Chemotaxis for Discreet, OTC Product
    GREENSBORO, N.C., April 13, 2022 /PRNewswire/ -- AT Research Partners has been granted US patent #11,298,375, Brady, et.al.
  • This invention addresses that need, offering a global opportunity in the FemTech space."
  • The patent leverages other spermatozoa properties that include the chemotactic drivers that normally draw them to fertile ova -and their competitive response to ambient signals.
  • AT Research Partners is seeking a pharma or FemTech partner to help develop and manufacture the invention.

Novel Contraceptive by AT Research Partners Promises Efficacy, Access and Safety for Women Using Nanotechnology

Retrieved on: 
Monday, November 15, 2021

One of the patent-pending formulations would allow for continuous protection from as few as 2 applications per week with a biologically neutral contraceptive.

Key Points: 
  • One of the patent-pending formulations would allow for continuous protection from as few as 2 applications per week with a biologically neutral contraceptive.
  • The time is now for this innovation,' said lead inventor, Terry E. Brady, a 75-year-old with several patent credits to his name.
  • "It is a totally new approach to prevent pregnancy using nanoparticles bound to disruptive atoms that can rupture the tiniest cells in the human body, spermatozoa.
  • At the same time, development of new contraceptive technologies is chronically underfunded, and investments have remained stagnant for years."